MBX Biosciences to Participate in the Oppenheimer 33rd Annual Healthcare Conference
07 mars 2023 08h00 HE
|
MBX Biosciences, Inc.
CARMEL, Ind., March 07, 2023 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of...
MBX Biosciences to Participate in the SVB Securities Global Biopharma Conference
24 janv. 2023 08h00 HE
|
MBX Biosciences, Inc.
CARMEL, Ind., Jan. 24, 2023 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of...
MBX Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference
05 janv. 2023 08h00 HE
|
MBX Biosciences, Inc.
CARMEL, Ind., Jan. 05, 2023 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of...
MBX Biosciences Closes $115 Million Series B Financing to Advance Development of Endocrine Disease Programs
14 nov. 2022 08h00 HE
|
MBX Biosciences, Inc.
CARMEL, Ind., Nov. 14, 2022 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of...
MBX Biosciences Advances Phase 1 Clinical Trial of Long-Acting Parathyroid Hormone Peptide Prodrug, MBX 2109
05 oct. 2022 09h00 HE
|
MBX Biosciences, Inc.
CARMEL, Ind., Oct. 05, 2022 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of...
MBX Biosciences Receives Orphan Drug Designation for Lead Candidate MBX 2109 for the Treatment of Hypoparathyroidism
26 juil. 2022 12h00 HE
|
MBX Biosciences, Inc.
CARMEL, Ind., July 26, 2022 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing precision endocrine peptide therapeutics to treat endocrine disorders,...
MBX Biosciences Appoints Richard B. Bartram as Chief Financial Officer
11 avr. 2022 07h30 HE
|
MBX Biosciences, Inc.
CARMEL, Ind., April 11, 2022 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing peptide therapeutics with a focus on the treatment of endocrine...
MBX Biosciences Appoints Ora Hirsch Pescovitz, M.D., to Board of Directors
05 avr. 2022 08h00 HE
|
MBX Biosciences, Inc.
CARMEL, Ind., April 05, 2022 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing peptide therapeutics with a focus on the treatment of endocrine...